Cargando…

Levomilnacipran for the treatment of major depressive disorder: a review

Levomilnacipran (LVM, Fetzima(®)) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including duloxetine,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asnis, Gregory M, Henderson, Margaret A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295915/ https://www.ncbi.nlm.nih.gov/pubmed/25657584 http://dx.doi.org/10.2147/NDT.S54710

Ejemplares similares

The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review
por: Bruno, Antonio, et al.
Publicado: (2016)

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
por: Freeman, Marlene P., et al.
Publicado: (2016)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang, Qunlian, et al.
Publicado: (2016)

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2016)

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
por: Montgomery, Stuart A., et al.
Publicado: (2014)

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study
por: Durgam, Suresh, et al.
Publicado: (2019)

Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
por: Wesnes, Keith A., et al.
Publicado: (2017)

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
por: Sambunaris, Angelo, et al.
Publicado: (2014)

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans
por: Chen, Laishun, et al.
Publicado: (2015)

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
por: Gommoll, Carl P., et al.
Publicado: (2014)

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
por: Sambunaris, Angelo, et al.
Publicado: (2014)

EMSAM (deprenyl patch): how a promising antidepressant was underutilized
por: Asnis, Gregory M, et al.
Publicado: (2014)

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
por: Montgomery, Stuart A., et al.
Publicado: (2014)

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre, Roger S
Publicado: (2017)

Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians
por: Asnis, Gregory M., et al.
Publicado: (2015)

Disposition and metabolism of [(14)C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats
por: Brunner, Valérie, et al.
Publicado: (2015)

Treatment of Major Depressive Disorder in Pediatric Populations
por: Neavin, Drew R., et al.
Publicado: (2018)

Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
por: McCarthy, Brian, et al.
Publicado: (2023)

Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review
por: Andrade, Pablo, et al.
Publicado: (2010)

Neuronal connectivity in major depressive disorder: a systematic review
por: Helm, Katharina, et al.
Publicado: (2018)

Rediscovering Trazodone for the Treatment of Major Depressive Disorder
por: Fagiolini, Andrea, et al.
Publicado: (2012)

Pharmacological Treatment of Major Depressive Disorder in Adolescents
por: Farley, Rachel L.
Publicado: (2005)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

The Importance of Epigenetics in Diagnostics and Treatment of Major Depressive Disorder
por: Czarny, Piotr, et al.
Publicado: (2021)

Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
por: Kaur, Mandeep, et al.
Publicado: (2021)

Major depressive disorder: Validated treatments and future challenges
por: Karrouri, Rabie, et al.
Publicado: (2021)

Role of trazodone in treatment of major depressive disorder: an update
por: Fagiolini, Andrea, et al.
Publicado: (2023)

Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review
por: Kuburi, Sarah, et al.
Publicado: (2022)

Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review
por: Vasiliu, Octavian
Publicado: (2023)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

SUMOylation and Major Depressive Disorder
por: Jeoung, Seok-Won, et al.
Publicado: (2022)

Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses
por: Simon, Maria S, et al.
Publicado: (2023)

Effects of neurofeedback on major depressive disorder: a systematic review
por: Dobbins, Isabelly Cristine de Souza, et al.
Publicado: (2023)

Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
por: Zimovetz, Evelina A, et al.
Publicado: (2012)

Nightmares in Patients with Major Depressive Disorder, Bipolar Disorder, and Psychotic Disorders: A Systematic Review
por: Akkaoui, Marine Ambar, et al.
Publicado: (2020)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
por: Hellerstein, David J, et al.
Publicado: (2015)

Prevalence and correlates of major depressive disorder: a systematic review
por: Gutiérrez-Rojas, Luis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tvjooos0oc2e1ut4j4bjnd6tqc